Susquehanna Fundamental Investments’s Takeda Pharmaceutical TAK Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,700	Closed	-$231K	–	578
2023 Q2	$231K	Hold	14,700	–	–	0.01%	563
2023 Q1	$242K	Hold	14,700	–	–	0.01%	827
2022 Q4	$229K	Sell	14,700 -40,350	-73%	-$564K	﹤0.01%	1049
2022 Q3	$714K	Buy	+55,050	New	+$765K	0.01%	906

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna Fundamental Investments's TAK Position: Q3 2023 in Review

Susquehanna Fundamental Investments sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 14,700 shares — an estimated $231K sold.

Susquehanna Fundamental Investments first reported a position in TAK in Q3 2022 and held it in 4 quarters. The position peaked at $714K in Q3 2022. 313 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Susquehanna Fundamental Investments reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 14,700 Takeda Pharmaceutical shares in Q3 2023, an estimated $231K.
Susquehanna Fundamental Investments first reported a position in Takeda Pharmaceutical in Q3 2022 and held it in 4 quarters.
Susquehanna Fundamental Investments's Takeda Pharmaceutical position peaked at $714K in Q3 2022.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2023, filed 14 Nov 2023.